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The aim of this study was to evaluate whether rosuvastatin (HMG-CoA reductase inhibitor) modulates the carbohydrate
and lipid metabolism, the development of non-alcoholic fatty liver disease (NAFLD), and the increase in body mass in a
model of diet-induced obesity. Male C57Bl/6 mice (3-months-old) were fed a high-fat diet (HF, 60% lipids) or the
standard chow (SC, 10% lipids) for 15 weeks. The animals were then treated with 10 mg/kg/day (HF-R10 group), 20
mg/kg/day (HF-R20), or 40 mg/kg/day (HF-R40) of rosuvastatin for five weeks. The HF diet led to glucose intolerance,
insulin resistance, weight gain, increased visceral adiposity with adipocyte hypertrophy, and hepatic steatosis (micro
and macrovesicular). The rosuvastatin treatment decreased the adiposity and the adipocyte size in the HF-R10 and
HF-R20 groups. In addition, rosuvastatin changed the pattern of fat distribution in the HF-R40 group because more fat
was stored subcutaneously than in visceral depots. This redistribution improved the fasting glucose and the glucose
intolerance. Rosuvastatin also improved the liver morphology and ultrastructure in a dose-dependent manner.
In conclusion, rosuvastatin exerts pleiotropic effects through a dose-dependent improvement of glucose intolerance,
insulin sensitivity and NAFLD and changes the fat distribution from visceral to subcutaneous fat depots in a mouse
model of diet-induced obesity.
Keywords: Rosuvastatin, Insulin resistance, Adipose tissue, NAFLDBackground
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of chronic liver disease and encompasses
a number of diseases, from steatosis (lipid deposition)
and non-alcoholic steatohepatitis (NASH, inflammation)
to cirrhosis (fibrosis) and liver failure [1]. It affects up to
20% of the population in Western countries [2] and is
commonly found in patients with visceral obesity, insulin
resistance, dyslipidemia and hypertension [3]. Anatomic-
ally, steatosis can take one of two forms depending on
the size of the lipid vesicles: microvesicular steatosis is
the condition in which fat is stored in multiple small* Correspondence: jjcarv@gmail.com
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distribution, and reproduction in any mediumvesicles within the hepatocyte cytoplasm, whereas
macrovesicular steatosis refers to the condition in which
fat is stored in a single large vesicle [4]. The exact phy-
siopathology of NAFLD and especially the factors that
lead to the progression from steatosis to steatohepatitis
and end-stage liver disease are not fully understood [3].
Promising treatments for NASH include antioxidants,
hepatoprotective agents, antidiabetic drugs, such as insulin
sensitizers, and lipid-lowering agents [5,6]. Rosuvastatin is
a lipid-lowering agent that competitively inhibits the
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase. Rosuvastatin exhibits the highest efficacy in the
reduction of LDL cholesterol, total cholesterol and triglyc-
erides compared with other statins at comparable doses
[7]. It has been shown that rosuvastatin has an increased
number of binding sites to the HMG-CoA reductase en-
zyme compared with other statins, which would explain
its stronger inhibition capability and thus its greater thera-
peutic efficacy. Moreover, rosuvastatin has been found toentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Composition and energy content of the SC and
HF diet I cal = 4.184J
Content (g/kg) Diet
SC HF
Casein (≥85% of protein) 140.0 190.0
Cornstarch (g/kg) 620.7 250.7
Sucrose (g/kg) 100.0 100.0
Soya-bean oil (g/kg) 40.0 40.0
Lard (g/kg) 320.0
Fibre (g/kg) 50.0 50.0
Vitamin mix (g/kg)* 10.0 10.0
Mineral mix (g/kg)* 35.0 35.0
L-cystin (g/kg) 1.8 1.8
Choline (g/kg) 2.5 2.5
Antioxidant (g/kg) 0.008 0.008
Total mass (g) 1.000 1.000
Energy content (kcal/kg) 3.573 5.404
Carbohydrates (%) 76 26
Protein (%) 14 14
Lipids (%) 10 60
*Mineral and vitamin mmixtures are in accordance with AIN 93M.
Neto-Ferreira et al. Diabetology & Metabolic Syndrome 2013, 5:32 Page 2 of 10
http://www.dmsjournal.com/content/5/1/32be a highly effective hypolipidemic agent in patients with
metabolic syndrome [8]. In addition, rosuvastatin reduces
the risk of cardiovascular disease, decrease vascular reactive
oxygen species generation independently of cholesterol re-
duction [9] and exerts several “pleiotropic”, but also achieve
significant improvement in endothelial function [10] effects
that may result in a further clinical benefit [11,12].
Recent studies have shown that rosuvastatin amelio-
rates hepatic insulin resistance in rodents and humans
[13,14]. Even with some concern in relation to safety,
the use of statins to tackle NAFLD has been encouraged
by “ National Lipid Association ” [15], mainly consider-
ing positive results from important trials such as JUPI-
TER in which patients at high risk to new diabetes onset
also benefited from rosuvastatin use [16]. However, stud-
ies evaluating the use of statins to treat insulin resistance
and NAFLD are scarce in the literature.
Given the increasing prevalence of obesity, the re-
search community is seeking experimental models that
both mimic the human phenotype and are suitable for
testing potential therapies to treat metabolic syndrome
(MS) and other associated metabolic disorders [17].
C57Bl/6 mice fed a high-fat (HF) diet are a useful ex-
perimental model for studying MS, as has been shown
in previous studies [18,19]. Thus, the aim of the present
study was to evaluate whether rosuvastatin modulates
the carbohydrate and lipid metabolism, the level of non-
alcoholic fatty liver disease (NAFLD), and the body mass
gain in a model of diet-induced obesity.
Methods
Experimental groups
All of the procedures were conducted in accordance
with the conventional guidelines for animal experimen-
tation (NIH Publication No. 85–23, revised in 1996). All
of the experimental protocols were approved by the ani-
mal ethics committee of the State University of Rio de
Janeiro. The animals were housed under controlled con-
ditions (temperature at 21±2°C, humidity at 60±10% and
a 12-h/12-h dark/light cycle) and had free access to food
and water. The mineral and vitamin contents of the two
diets were identical and were consistent with the American
Institute of Nutrition’s recommendation (AIN 93M) [20].
The mouse chow was prepared by Pragsolucoes (Jau, São
Paulo, Brazil).
At baseline, after one week of acclimatization, 50
three-month-old C57Bl/6 male mice were randomly di-
vided and fed different diets during a 15-week period,
which included a SC diet (standard chow; 10% lipids,
n=10) or a HF diet (60% lipids, n=40), both diets are de-
tailed in Table 1. The 15 week period of administration
of HF diet aimed at inducing the main features of the
metabolic syndrome. Before being divided into two
groups, the homoscedasticity of variances was tested andall animals followed the normal distribution and had not
differences concerning body mass, which guarantee that
different groups started the experiment without any dif-
ference that could add bias to the study.
Afterwards, the HF group was randomly divided into 4
groups (n=10 each) in order to begin treatment with
rosuvastatin (Crestor; Astrazeneca). Consequently, five
groups were formed, as follows: SC group (standard
chow during the whole experiment / n=10); HF group
(high fat diet during the whole experiment /n=10); HF-
R10 group (high fat diet plus rosuvastatin, 10 mg/kg/day /
n=10); HF-R20 group (high fat diet plus rosuvastatin, 20
mg/kg/dia / n=10); HF-R40 group (high fat diet plus
rosuvastatin, 40 mg/kg/dia / n=10). Treatments lasted for
5 weeks and drug was mixed with the diet. Fresh chow
was provided daily, and any remaining chow from the pre-
vious day was discarded. The food intake was evaluated
daily (1 p.m.), and the body mass was measured weekly.
Taking daily food consumption and BM into account, the
drug doses were corrected to match the same concentra-
tions as indicated.
The energy contents in the high-fat diet and the stand-
ard show were 5.404 kcal/g and 3.573 kcal/g, respect-
ively. The feed efficiency was assessed after 15 weeks of
the SC or HF diet intake (pre-treatment) and after treat-
ment (post-treatment) as the energy intake in KJ divided
by body mass in g, expressed as KJ/g BM [6].
Concerning the endpoints evaluated, five animals from
each group were chosen at random for stereological and
Figure 1 Initial and finish body mass. Mice were fed the standard
chow (SC) or a high-fat diet (HF) for 15 weeks. The mice then
received five weeks of rosuvastatin at doses of 10 mg/kg/day
(HF-R10), 20 mg/kg/day (HF-R20), or 40 mg/kg/day (HF-R40). The
symbols indicate a difference compared with [a] the SC group, [b]
the HF group, [c] the HF-R10 group and [d] the HF-R20 group.
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used for western blotting and transmission electron micros-
copy. All analyses were carried out in a blinded fashion.
Oral glucose tolerance test (OGTT)
To evaluate the glucose tolerance, an OGTT was
performed after 15 weeks of diet intake (before treat-
ment) and again five weeks after treatment. The animals
fasted for 6 h and then received 25% glucose in sterile
saline (0.9% NaCl) at a dose of 1 g/kg by orogastric gav-
age. The blood was collected through a little incision at
the tip of the tail, and the plasma glucose concentration
was measured (glucometer; Accu-Chek Active; Roche
Applied Science, Brazil). The plasma glucose was
assessed before glucose administration and 15, 30, 45
and 120 min after glucose administration. The response
was expressed as the area under the curve (AUC)
(GraphPad Prism version 5.03; San Diego, CA, USA).
Blood biochemistry
The animals were food-deprived for 6 h and then deeply
anaesthetized with sodium pentobarbital (150 mg/kg i.p.).
The blood was sampled by cardiac puncture at the right
atrium and then centrifuged (120×g for 15 min) at room
temperature. The total cholesterol (TC), triglycerides
(TG), and markers of hepatic function, such as aspartate
aminotransferase (AST) and alanine aminotransferase (ALT),
in the serum were measured by a colorimetric enzymatic
assay (Bioclin, Quibasa, Belo Horizonte, MG, Brazil).
The insulin level was determined by radioimmuno-
assay (cat. no. RI-13K; Linco/Millipore; intra-assay coef-
ficient of variation of 1.4%). The insulin resistance (IR)
was estimated through the homeostasis model assess-
ment index (HOMA-IR): (insulin × glucose)/ 22.5 [21].
Hepatic triglyceride
Liver samples were frozen at −80°C. The level of hepatic
triglycerides was measured according to a previously pub-
lished protocol [22]. Briefly, 50 mg of frozen liver tissue
was placed in an ultrasonic processor with 1.0 mL of iso-
propanol. The homogenate was centrifuged at 2,000 × g
and 5.0 μl of the supernatant was used. The hepatic trigly-
ceride was then assessed using a colorimetric enzymatic
assay (K55, Bioclin, Quibasa, Belo Horizonte, MG, Brazil).
Liver stereology
Several fragments from all parts of the liver were pre-
pared, included in Paraplast Plus (Sigma Aldrich, St.
Louis, MO, USA), sectioned into 3-μm sections and
stained with hematoxylin–eosin. Five random micro-
scopic fields were analyzed per animal through the use
of video-microscopy (Leica DMRBE microscope with
plan achromatic objectives, Leica, Wetzlar, Germany)
and a 36-point test-system (PT) [23]. The volumedensity (Vv) of steatosis was estimated by point counting
the fat droplets in the hepatocytes: Vv [steatosis] = PP
[steatosis] / PT, where PP is the number of points that
hit the lipid droplets [24].
Liver ultrastructure
The liver samples were processed for transmission
electron microscopy. Ultra-thin sections (Leica Ultracut
ultramicrotome) were counterstained with uranyl acetate
and lead citrate and observed with a Zeiss EM 906. The
number density of mitochondria (QA) was defined as the
number of mitochondrial profiles within a frame with a
known area (expressed as the number of mitochondria/
μ2). A total of 45 electron micrographs was evaluated
per group, and all of the mitochondria within the test
frame, except those that hit the forbidden lines or their
extensions, were counted [25].
Adipocyte morphometry
After euthanasia, the epididymal (visceral fat) and in-
guinal (subcutaneous fat) fat pads were collected and
weighed, and these values were used to calculate the vis-
ceral: subcutaneous (Visc:Sub) fat ratio. Histological slices
of the epididymal fat pad were prepared, and digital im-
ages were obtained (LC Evolution camera; Olympus BX51
microscope and Media Cybernetics Image-Pro Plus ver-
sion 7.0; TIFF format; 36-bit color; 1, 280 × 1,024 pixels).
The mean cross-sectional area of at least 50 adipocytes
per mice was estimated [26].
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The total hepatic proteins were extracted in homogeniz-
ing buffer with protease inhibitors. The homogenates
were then centrifuged at 3200 × g and 4°C for 20 min,
and the supernatants were collected. Equal quantities of
total protein were resuspended in SDS-containing
sample buffer, heated for 5 min at 100°C and separated
by SDS/PAGE. After electrophoresis, the proteins were
electroblotted onto PVDF transfer membranes (Hybond-
P; Amersham Biosciences) and visualized with Ponceau
solution staining. The membranes were then blocked by
incubation in 6% (w/v) non-fat dry milk in TBS-T (Tris-
buffered saline [20 mmol/l Tris/HCl pH 7.4 and 500
mmol/l NaCl] with 0.05% Tween-20), incubated with
polyclonal antibodies against rabbit SREBP-1 (sterol
regulatory element-binding protein-1; 68 kDa; SC-367;
Santa Cruz Biotechnology), washed and incubated with
anti-rabbit IgG secondary antibody. The SREBP-1 pro-
tein expression was detected using an ECL (enhanced
chemiluminescence) detection system (Amersham
Biosciences). The signals were visualized by autoradiog-
raphy and quantified through a quantitative analysis
of the digital images (Image-Pro Plus version 7.0).
The integral absorbance values were measured. The
structural b-actin proteins (Santa Cruz Biotechnology,
code sc-81178, CA, USA) were obtained by stripping
the nitrocellulose membrane proteins of the liver
tissue.Table 2 Feeding behavior, carbohydrate metabolism and bloo
Parameters
Pre-treatment SC HF
Food intake (g/day) 2.9±0.01 3.7±0.03
Energy (kJ/day per mouse) 43.4±0.34 83.7±0.64a
OGTT (AUC) 1,174 ±46.55 1,259±45.06a
Post-treatment SC HF
Food intake (g/day) 2.2±0.01 2.7±0.02 a
Energy (kJ/day per mouse) 32.6±0.2 60.4±1.1a
Feed efficiency (kJ/g BM) 1.2±0.02 1.6±0.05a
Glucose (mg/dL) 109±6.22 149.6±9.9a
Insulin (mU/ml) 5.85±0.95 20.4±2.0a
OGTT (AUC) 990.1±37.8 1,264.2±41.8a
HOMA-IR 1.79±0.23 7.51±0.81a
Serum TC (mg/dL) 103.6±18.1 226.2±16.0a
Serum TG (mg/dL) 51.0±4.6 87.1±4.8a
ALT (U/L) 15±2.9 115±15.2a
AST (U/L) 272±28.1 289±35.4
Abbreviations: SC standard rodent chow, HF high-fat diet, HF-R10 10 mg/kg/day of
rosuvastatin, OGTT oral glucose tolerance teste, AUC area under the curve, HOMA-IR
aminotransferase, AST aspartate transaminase, TC total cholesterol, TG triglyceride. S
[d] HF-R20 group.Data analysis
The values are shown as the means ± SEM. In all of the
cases in which homoscedasticity among the variances
was confirmed, the data were analyzed using ANOVA
followed by post-hoc Tukey’s test. If homoscedasticity
was not confirmed, the differences were analyzed using
the Kruskal-Wallis test and the post-hoc Dunn’s test. A
P value ≤ 0.05 was considered statistically significant
(GraphPad Prism version 5.03 for Windows).
Results
Body mass and food intake
The body mass (BM) of the mice fed the HF diet for 15
weeks increased progressively compared to the animals
that received the standard chow (p <0.001, Figure 1).
After five weeks of rosuvastatin treatment (20 weeks on
the respective diet), the BM remained greater in the HF,
HF-R10 and HF-R20 groups compared with the SC
group. The 40 mg/kg/day dose of rosuvastatin reduced
the body mass gain of the HF-R40 group. The HF-R40
group exhibited a lower BM than the HF, HF-R10 and
HF-R20 groups (p <0.001, Figure 1).
After ratifying the body mass gain in the HF group, we
found an increased food intake and a higher energy
intake in these animals (+23% and +85% respectively,
p <0.0001, Table 2). Despite the lower increment in body
mass observed in the HF-R40 mice, the administration
of rosuvastatin dose-dependently increased the foodd biochemistry
Groups
HF-R10 HF-R20 HF-R40
2.8±0.02 a,b 2.9±0.02 a,b 3.0±0.01 a,b,c,d
63.7±0.5a,b 64.6±0.4a,b 68.5±0.2a,b,c,d
1.8±0.07 a 1.8±0.05a,b 2.2±0.05 a,b,c,d








rosuvastatin, HF-R20 20 mg/kg/day of rosuvastatin, HF-R40 40 mg/kg/day of
homeostasis model assessment index for insulin resistance, ALT alanine
ymbols represent difference with: [a] SC group; [b] HF group; [c] HF-R10 group;
Table 3 Adipose tissue weight and morphology
Parameters Groups
SC HF HF-R10 HF-R20 HF-R40







































Abbreviations: SC standard rodent chow, HF high-fat diet, HF-R10 10 mg/kg/
day of rosuvastatin, HF-R20 20 mg/kg/day of rosuvastatin, HF-R40 40 mg/kg/
day of rosuvastatin, Sub subcutaneous fat (=inguinal fat), Visc visceral fat
(=epididymal plus retroperitoneal fat). Symbols represent difference with: [a]
SC group; [b] HF group; [c] HF-R10 group; [d] HF-R20 group.
Figure 2 Pleiotropic effects of rosuvastatin on the liver
morphology. Mice were fed the standard chow (SC) or a high-fat
diet (HF) for 15 weeks and then received five weeks of rosuvastatin
treatment at doses of 10 mg/kg/day (HF-R10), 20 mg/kg/day (HF-
R20), or 40 mg/kg/day (HF-R40). (A) Liver weight corrected by tibia
length. (B) Hepatic triglyceride content. The symbols indicate a
difference compared with [a] the SC group, [b] the HF group and [c]
the HF-R10 group.
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HF-R40 groups compared with the untreated HF group.
Feed efficiency was evaluated through the ratio KJ/g BM
and behaved likewise energy intake, where HF group
showed the highest feed efficiency (+30% in comparison
to SC, p <0.0001), followed by the rosuvastatin treated
animals in a dose dependant manner, being feed effi-
ciency of HF-R40 bigger than HF-R20 and HF-R10
(+22%, p <0.05).
Carbohydrate metabolism
The mice from the HF group exhibited glucose intoler-
ance after 15 weeks on the HF diet (pre-treatment,
Table 2). Before rosuvastatin treatment, the AUC of the
OGTT was higher in the HF mice than in the SC mice
(7% higher, p <0.01). This difference was still observed at
the end of the experiment. The administration of
rosuvastatin at doses of 20 and 40 mg/kg/day improved
the glucose intolerance. The AUC of the OGTT was
lower in the HF-R20 (−17%, p <0.001) and HF-R40
(−32%, p <0.05) groups compared with the HF group
(Table 2).
At the end of the experiment, the HF mice were also
insulin-resistant compared with the mice that were fed
the standard chow (HOMA-IR was 25% higher in the
HF group, p <0.05). The three doses of rosuvastatin im-
proved the insulin sensitivity. The HOMA-IR was 11%
lower in the HF-R10 group compared with the HF group
(p <0.01) and much lower in the HF-R40 group (−70%)
compared with the HF-R10 group (p <0.01, Table 2).
Blood biochemistry
The total cholesterol (TC) increased in the untreated HF
mice compared with the SC group (+119% higher,
p <0.01), and the three doses of rosuvastatin reduced the
TC (p <0.001, Table 2). The same pattern was observed
with the serum triglycerides (TG) (Table 2). The plasma
ALT concentration was also significantly elevated in the
untreated HF mice compared with the SC (p <0.0001)
and HF-R40 groups (p <0.0271). The plasma AST did
not differ among groups.
Adipose tissue
The high-fat diet increased the visceral fat mass (retro-
peritoneal and epididymal fat pads, Table 3). This fat
mass was significantly greater in the HF group (+605%,
p <0.001) than in the SC group, and the 10 mg/kg/day
and 20 mg/kg/day doses of rosuvastatin did not affect it
(+455% and +386% in the HF-R10 and HF-R20 groups,
respectively, compared with the SC group, p <0.05). In
contrast, the visceral fat mass decreased in the mice
treated with 40 mg/kg/day of rosuvastatin (−56% in the
HF-R40 group compared with the HF group, p <0.01) to
levels similar to those measured in the SC group. The
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cantly higher in the HF-R10 and HF groups than in the
SC group (+312%, p <0.01) (Table 3). In addition, the ad-
ministration of rosuvastatin changed the pattern of fat
distribution. The HF diet induced an increase in the
visceral fat, as shown by the Visc:Sub ratio (Table 3).
However, rosuvastatin was able to prevent the fat redis-
tribution from subcutaneous to visceral fat depots.
Hypertrophied adipocytes were observed in the HF
group. The adipocyte diameter was 109% higher
(p <0.001) in the HF group than in the SC group
(Table 3), and the rosuvastatin treatment had a dose-
dependent effect on this parameter. Only the HF-R40
group exhibited adipocytes with a diameter similar to
those observed in the SC group, whereas the other
groups (HF-R10 and HF-R20) had intermediate-sized
adipocytes.
Liver
Excessive fat intake led to liver enlargement in all of the
groups that received the HF diet compared with the SC
group (Figure 2A). The levels of hepatic triglycerides
were significantly higher in the HF group (+400%,
p = 0.0001) than in the SC group (Figure 2B). The ro-
suvastatin treatment dose-dependently decreased the
hepatic triglycerides in the mice from the HF-R10, HF-
R20 and HF-R40 groups compared with the untreatedFigure 3 Liver photomicrographs stained with hematoxylin and eosin
whereas the HF groups exhibit micro and macrovesicular steatosis. The ros
manner, as observed in the treated groups: HF-R10, HF-R20 and HF-R40. Th
compared with [a] the SC group, [b] the HF group and [c] the HF-R10 grouHF group (p <0.0001, Figure 2B). As observed through
light microscopy, liver steatosis was recurrent in our
study, especially in the HF group, which showed severe
microvesicular and macrovesicular steatosis (Figure 3).
Although both the HF-R20 and HF-R40 groups showed
an attenuation of the hepatic steatosis, only the HF-R40
group was statistically different from the untreated HF
group. The electron microscopy also revealed hepa-
tocytes with abundant lipid vesicles in the HF group
(Figure 4), which characterizes the existence of macro and
microvesicular steatosis and a complete breakdown of the
cytoarchitecture. Smaller and scarcer mitochondria were
also found. The mitochondrial cristae were difficult to ob-
serve, and a remarkable breakdown of the rough endo-
plasmic reticulum and Golgi apparatus was found
(Figure 4). In contrast, the treated groups showed smaller
and less frequent fat droplets, which confirms the findings
obtained through light microscopy. The untreated HF
mice exhibited a lower density of mitochondria compared
with the SC (p <0.001), HF-R20 (p <0.001) and HF-R40
(p <0.05) groups (Figure 4).
Western blot analysis
The SREBP-1 expression was higher in the untreated HF
group compared with the SC group (+614%, P <0.0001,
Figure 5). The administration of rosuvastatin, regardless
of the dosage used, decreased the SREBP-1 expression(bar = 30 μm). Note the normal liver morphology in the SC group,
uvastatin treatment ameliorated the steatosis in a dose-dependent
e arrows indicate the steatosis. The symbols indicate a difference
p.
Figure 4 Pleiotropic effects of rosuvastatin on the liver ultrastructure. Mice were fed the standard chow (SC) or a high-fat diet (HF) for 15
weeks, followed by five weeks of rosuvastatin treatment at doses of 10 mg/kg/day (HF-R10), 20 mg/kg/day (HF-R20), or 40 mg/kg/day (HF-R40).
Numerical density of mitochondria assessed by stereology. Electron micrographs of the liver (bar = 2 μm). The nucleus (N), nucleolus (Nu) and
rugous endoplasmic reticulum (RER) are well preserved, and a number of mitochondria (M) are observed in the SC group. The HF mice exhibit
severe macrovesicular (star) and microvesicular (arrow) steatosis, unorganized RER and few mitochondria. Microvesicular steatosis is also found in
the HF-R10 group. In contrast, the HF-R20 group has a regular cytoarchitecture, a typical number of mitochondria and spread lipid droplets.
A regular nucleus, nucleolus and mitochondria, as well as diminished steatosis, are observed in the HF-R40 group. The symbols indicate a
difference compared with [a] the SC group, [b] the HF group and [c] the HF-R10 group.
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HF-R20 and HF-R40 groups exhibited no difference
from the SC group.
Discussion
The present model of metabolic syndrome, which is
based on mice receiving a high-fat diet, is characterized
by obesity, insulin resistance, glucose intolerance,
dyslipidemia, and hepatic steatosis compatible with
NAFLD. All of these changes were either attenuated or
ameliorated by rosuvastatin in a dose-dependent man-
ner. It is important to highlight that the dose of 10 mg/Kg
mimics the usual clinical dose of humans following the
dose translation proposed recently [27], whereas the
largest doses are important to isolate the main effects in
rodents once they present a more accelerated metabolism
than humans and, hence, respond to bigger doses in the
same extent humans respond to a small one [14]. Of note,
the highest doses of rosuvastatin showed beneficialpleiotropic effects on the adipose tissue because it reduced
the body mass, the fat mass and the adipocyte size and
increased the subcutaneous fat mass (inguinal fat), as
evidenced by the Visc:Sub ratio.
Excessive circulating free fatty acids (FFAs) are stored
as ectopic fat in the muscle, liver and pancreas [28,29].
Thus, the visceral adipose tissue becomes mainly
responsible for the development of the metabolic
syndrome symptoms. In the present study, the HF diet
caused weight gain, visceral adiposity, and adipocyte
hypertrophy. The epididymal fat mass can ideally be
used to assess the percentage of body fat because it
correlates with the total body fat in humans [30]. A loss
in body weight is usually correlated with both improve-
ments in insulin sensitivity and reduced adipocyte size
[31]. The administration of a rosuvastatin dose of
40 mg/kg/day decreased the adipocyte size and changed
the pattern of fat storage because more fat was stored in
the subcutaneous depot in the mice that received this
Figure 5 Western blot analyses of hepatic SREBP-1. A
representative immunoblot is shown; the quantification of the bands
in the immunoblot is shown below. The values are the means ± S.E.
M. from five experiments. The symbols indicate a difference
compared with [a] the SC group, [b] the HF group and [c] the
HF-R10 group.
Neto-Ferreira et al. Diabetology & Metabolic Syndrome 2013, 5:32 Page 8 of 10
http://www.dmsjournal.com/content/5/1/32treatment. Although the 10 and 20 mg/kg/day doses of
rosuvastatin decreased the fat pad weight and the adipo-
cyte size, these did not change the fat distribution
between the visceral and subcutaneous depots. We did
not expect the observed change in the adipose tissue
biology; thus, further studies are necessary to obtain a
better comprehension of the mechanisms that regulate
the effect of rosuvastatin on adipose tissue.
Even though HF animals treated with rosuvastatin
showed decreased fat pad masses and body masses than
untreated HF animals, a progressive increase of feed
efficiency was perceived in the treated groups. We
hypothesize that effects of rosuvastatin upon lipid me-
tabolism, adipose tissue remodeling, insulin resistance
alleviation and NAFLD amelioration was so marked that
even with a larger intake of energy, animals treated with
20 mg/Kg and 40 mg/Kg of rosuvastatin had a better
body weight control than untreated and the ones treated
with 10 mg/Kg of the drug.
The mechanisms that lead to NAFLD development
vary and are associated with an unbalance of several cel-
lular processes related to the signaling pathways of insu-
lin, including the increased flow of FFA to the liver
(lipolysis), the de novo lipogenesis of FFA, decreased
beta-oxidation, mitochondrial dysfunction, oxidative
stress, and endoplasmic reticulum stress [32]. Several evi-
dences show that NAFLD development is associated with
the amount of visceral fat, AST, ALT, total cholesterol, tri-
glycerides, serum insulin and insulin resistance, which is
assessed by the HOMA-IR.The administration of rosuvastatin (20 mg/kg/day) im-
proved the insulin sensitivity, decreased the liver
steatosis and the body weight, and improved the circu-
lating levels of cholesterol and triglycerides in mice fed a
HF diet [14]. In the present study, the untreated HF
mice exhibited increased levels of serum TG, TC and
ALT and hepatic steatosis (micro and macrovesicular).
Rosuvastatin reduced the steatosis in a dose-dependent
manner, likely due to a decreased input of FFAs and an
increased output of FFAs through increased beta-
oxidation. Weight loss is directly correlated with the re-
duction of fat depots, which in turn reduces the release
of FFAs [33].
Ob/ob mice that are fed polyunsaturated fatty acids
(PUFAs) exhibit improved steatosis, reduced triglyceride
storage in the liver, and the suppression of SREBP-1 ex-
pression [34]. In the present study, rosuvastatin had a
dose-dependent effect on the SREBP-1 expression in the
liver of mice fed the high-fat diet. SREBP-1 regulates not
only the synthesis but also the storage in the liver of
hepatic triglycerides [34]. Thus, from a therapeutic point
of view, this enzyme might be a good target for the
treatment of hepatic steatosis [35].
Some experimental evidence has shown that mito-
chondrial dysfunction has a crucial role in NAFLD
genesis through the depletion of the mitochondrial
DNA content, the reduction in the activity of the mito-
chondrial respiratory chain and deficient beta-oxidation
[36,37]. In the present study, the livers from untreated
HF mice had enlarged and morphologically unor-
ganized mitochondria, as previously described [38],
whereas the rosuvastatin-treated groups had numerous
mitochondria that were morphologically well organized.
Because this organelle is the main organelle responsible
for beta-oxidation, these findings corroborate the hy-
pothesis that increased beta-oxidation is essential for the
prevention and/or reduction of hepatic damage in treated
animals [39].
The analysis of the carbohydrate metabolism showed
that the oral administration of glucose increases the
release of insulin from pancreatic beta-cells [40], but
the effect of statins on both carbohydrate metabolism
and insulin resistance is still controversial [41].
Our main results agree with the latest evidence from
epidemiological studies, reinforcing the importance of
translational studies, which shed light on many pathways
involved with the endpoints observed in humans.
Recently, the randomized, placebo-controlled JUPITER
(Justification for Use of statins in Prevention:an Interven-
tion Trial Evaluating Rosuvastatin), a trial of rosuvas-
tatin 20 mg, revealed a small risk of developing
diabetes under statin therapy was limited to partici-
pants who had biochemical evidence of impaired
fasting glucose or multiple components of metabolic
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benefits of statin therapy surpassed the hazard of de-
veloping new onset diabetes both in participants with
and without diabetes risk factors [16].
It is known that rosuvastatin has beneficial effects
on the carbohydrate metabolism in non-diabetic patients
with dyslipidemia compared with atorvastatin [42].
Fraulob et al. demonstrated that 20 mg of rosuvastatin
ameliorates hepatic steatosis and glucose intolerance in
a murine model of IR [14]. Corroborating these data, we
found an improvement in the fasting glucose and glu-
cose intolerance in mice treated for five weeks with
rosuvastatin at a dose of 20 or 40 mg/kg/day. The ana-
lysis of the insulin resistance showed that similar doses
of rosuvastatin and atorvastatin have the same effect on
the HOMA-IR after eight weeks of treatment.
In conclusion, rosuvastatin improves glucose intoler-
ance, insulin sensitivity and NAFLD in a dose-dependent
manner and changes the fat distribution from visceral to
subcutaneous fat depot in a mouse model of diet-
induced obesity. Consequently, rosuvastatin therapy may
be of great help to patients with metabolic syndrome be-
cause it has a wide range of beneficial pleiotropic effects.Limitations
This study presents some limitations. Firstly, the reduction
in body weight gain in the HFR group-40 when compared
with the other groups can be explained by a poor absorp-
tion of bowel function due to the high dosage of
rosuvastatin (40 mg) used in this group. Even though in-
testinal modifications were not identified as the stools
were normal without the presence of signs of intolerance
and malabsorption. Secondly, a prospective follow-up
study is needed to evaluate the effect of rosuvastatin treat-
ment at different doses upon weight reduction and im-
provement of insulin resistance in mice, once some of the
results found in the literature were in contrast with those
found in human studies.
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